1
|
Campos HM, Pereira RM, de Oliveira Ferreira PY, Uchenna N, Branco da Silva CR, Pruccoli L, Sanz G, Rodrigues MF, Vaz BG, Rivello BG, Batista da Rocha AL, de Carvalho FS, Oliveira GDAR, Lião LM, Georg RDC, Leite JA, Dos Santos FCA, Costa EA, Menegatti R, Tarozzi A, Ghedini PC. A novel arylpiperazine derivative (LQFM181) protects against neurotoxicity induced by 3- nitropropionic acid in in vitro and in vivo models. Chem Biol Interact 2024; 395:111026. [PMID: 38679115 DOI: 10.1016/j.cbi.2024.111026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2024] [Revised: 04/05/2024] [Accepted: 04/24/2024] [Indexed: 05/01/2024]
Abstract
In the pursuit of novel antioxidant therapies for the prevention and treatment of neurodegenerative diseases, three new arylpiperazine derivatives (LQFM181, LQFM276, and LQFM277) were synthesized through a molecular hybridization approach involving piribedil and butylated hydroxytoluene lead compounds. To evaluate the antioxidant and neuroprotective activities of the arylpiperazine derivatives, we employed an integrated approach using both in vitro (SH-SY5Y cells) and in vivo (neurotoxicity induced by 3-nitropropionic acid in Swiss mice) models. In the in vitro tests, LQFM181 showed the most promising antioxidant activity at the neuronal membrane and cytoplasmic levels, and significant neuroprotective activity against the neurotoxicity induced by 3-nitropropionic acid. Hence, this compound was further subjected to in vivo evaluation, which demonstrated remarkable antioxidant capacity such as reduction of MDA and carbonyl protein levels, increased activities of succinate dehydrogenase, catalase, and superoxide dismutase. Interestingly, using the same in vivo model, LQFM181 also reduced locomotor behavior and memory dysfunction through its ability to decrease cholinesterase activity. Consequently, LQFM181 emerges as a promising candidate for further investigation into its neuroprotective potential, positioning it as a new therapeutic agent for neuroprotection.
Collapse
Affiliation(s)
| | - Robbert Mota Pereira
- Institute of Biological Sciences, Federal University of Goias, Goiania, GO, Brazil
| | | | - Nkaa Uchenna
- Institute of Biological Sciences, Federal University of Goias, Goiania, GO, Brazil
| | | | - Letizia Pruccoli
- Department of Life Quality Studies, Alma Mater Studiorum - University of Bologna, Rimini, Italy
| | - Germán Sanz
- Chemistry Institute, Federal University of Goias, Goiania, GO, Brazil
| | | | | | - Bárbara Gonçalves Rivello
- Faculty of Pharmacy, Laboratory of Medicinal Pharmaceutical Chemistry, Federal University of Goias, Goiania, GO, Brazil
| | - André Luís Batista da Rocha
- Faculty of Pharmacy, Laboratory of Medicinal Pharmaceutical Chemistry, Federal University of Goias, Goiania, GO, Brazil
| | - Flávio Silva de Carvalho
- Faculty of Pharmacy, Laboratory of Medicinal Pharmaceutical Chemistry, Federal University of Goias, Goiania, GO, Brazil
| | | | | | | | | | | | - Elson Alves Costa
- Institute of Biological Sciences, Federal University of Goias, Goiania, GO, Brazil
| | - Ricardo Menegatti
- Faculty of Pharmacy, Laboratory of Medicinal Pharmaceutical Chemistry, Federal University of Goias, Goiania, GO, Brazil
| | - Andrea Tarozzi
- Department of Life Quality Studies, Alma Mater Studiorum - University of Bologna, Rimini, Italy
| | - Paulo César Ghedini
- Institute of Biological Sciences, Federal University of Goias, Goiania, GO, Brazil.
| |
Collapse
|
2
|
Choudhary D, Kumar B, Kaur R. Nitrogen-containing heterocyclic compounds: A ray of hope in depression? Chem Biol Drug Des 2024; 103:e14479. [PMID: 38361139 DOI: 10.1111/cbdd.14479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 01/12/2024] [Accepted: 01/31/2024] [Indexed: 02/17/2024]
Abstract
Depression is not similar to daily mood fluctuations and temporary emotional responses to day-to-day activities. Depression is not a passing problem; it is an ongoing problem. It deals with different episodes consisting of several symptoms that last for at least 2 weeks. It can be seen for several weeks, months, or years. At its final stage, or can say, in its worst condition, it can lead to suicide. Antidepressants are used to inhibit the reuptake of the neurotransmitters by some selective receptors, which increase the concentration of specific neurotransmitters around the nerves in the brain. Drugs that are currently being used for the management of various types of depression include selective serotonin reuptake inhibitors, tricyclic antidepressants, atypical antidepressants, serotonin, noradrenaline reuptake inhibitors, etc. In this review, we have outlined different symptoms, causes, and recent advancements in nitrogen-containing heterocyclic drug candidates for the management of depression. This article highlights the various structural features along with the structure-activity relationship (SAR) of nitrogen-containing heterocyclics that play a key role in binding at target sites for potential antidepressant action. The in silico studies were carried out to determine the binding interactions of the target ligands with the receptor site to determine the potential role of substitution patterns at core pharmacophoric features. This article will help medicinal chemists, biochemists, and other interested researchers in identifying the potential pharmacophores as lead compounds for further development of new potent antidepressants.
Collapse
Affiliation(s)
- Diksha Choudhary
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India
| | - Bhupinder Kumar
- Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Srinagar, Uttarakhand, India
- Department of Chemistry, Graphic Era (Deemed to be University), Dehradun, Uttarakhand, India
| | - Rajwinder Kaur
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India
| |
Collapse
|
3
|
Choudhary D, Kaur R, Singh TG, Kumar B. Pyrazoline Derivatives as Promising MAO-A Targeting Antidepressants: An Update. Curr Top Med Chem 2024; 24:401-415. [PMID: 38318823 DOI: 10.2174/0115680266280249240126052505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 01/06/2024] [Accepted: 01/17/2024] [Indexed: 02/07/2024]
Abstract
Depression is one of the key conditions addressed by the Mental Health Gap Action Programme (mhGAP) of WHO that can lead to self-harm and suicide. Depression is associated with low levels of neurotransmitters, which eventually play a key role in the progression and development of mental illness. The nitrogen-containing heterocyclic compounds exhibit the most prominent pharmacological profile as antidepressants. Pyrazoline, a dihydro derivative of pyrazole, is a well-known five-membered heterocyclic moiety that exhibits a broad spectrum of biological activities. Many researchers have reported pyrazoline scaffold-containing molecules as potential antidepressant agents with selectivity for monoamine oxidase enzyme (MAO) isoforms. Several studies indicated a better affinity of pyrazoline-based moiety as (monoamine oxidase inhibitors) MAOIs. In this review, we have focused on the recent advancements (2019-2023) in the development of pyrazoline-containing derivatives exhibiting promising inhibition of MAO-A enzyme to treat depression. This review provides structural insights on pyrazoline-based molecules along with their SAR analysis, in silico exploration of binding interactions between pyrazoline derivatives and MAO-A enzyme, and clinical trial status of various drug molecules against depression. The in-silico exploration of potent pyrazoline derivatives at the active site of the MAOA enzyme will provide further insights into the development of new potential MAO-A inhibitors for the treatment of depression.
Collapse
Affiliation(s)
- Diksha Choudhary
- Chitkara College of Pharmacy, Chitkara University, Punjab, 140401, India
| | - Rajwinder Kaur
- Chitkara College of Pharmacy, Chitkara University, Punjab, 140401, India
| | | | - Bhupinder Kumar
- Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Srinagar, Garhwal, Uttarakhand, 246174, India
- Department of Chemistry, Graphic Era (Deemed to be University), Dehradun, 248002, Uttrakhand, India
| |
Collapse
|
4
|
Andreozzi G, Ambrosio MR, Magli E, Maneli G, Severino B, Corvino A, Sparaco R, Perissutti E, Frecentese F, Santagada V, Leśniak A, Bujalska-Zadrożny M, Caliendo G, Formisano P, Fiorino F. Design, Synthesis and Biological Evaluation of Novel N-Arylpiperazines Containing a 4,5-Dihydrothiazole Ring. Pharmaceuticals (Basel) 2023; 16:1483. [PMID: 37895954 PMCID: PMC10609883 DOI: 10.3390/ph16101483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 10/03/2023] [Accepted: 10/16/2023] [Indexed: 10/29/2023] Open
Abstract
Arylpiperazines represent one of the most important classes of 5-HT1AR ligands and have attracted considerable interests for their versatile properties in chemistry and pharmacology, leading to the research of new derivatives that has been focused on the modification of one or more portions of such pharmacophore. An efficient protocol for the synthesis of novel thiazolinylphenyl-piperazines (2a-c) and the corresponding acetylated derivatives was used (3a-c). The new compounds were tested for their functional activity and affinity at 5-HT1A receptors, showing an interesting affinity profile with a Ki value of 412 nM for compound 2b. The cytotoxic activity of novel thiazolinylphenyl-piperazines (2a-c) and corresponding N-acetyl derivatives (3a-c) against human prostate and breast cancer cell lines (LNCAP, DU-145 and PC-3, MCF-7, SKBR-3 and MDA-MB231) was investigated according to the procedure described in the literature. The reported data showed a cytotoxic effect for 2a-c and 3a-c compounds (IC50 values ranging from 15 µM to 73 µM) on the investigated cancer cell lines, with no effect on noncancer cells. Future studies will be aimed to investigate the mechanism of action and therapeutic prospects of these new scaffolds.
Collapse
Affiliation(s)
- Giorgia Andreozzi
- Dipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano, 49, 80131 Naples, Italy; (G.A.); (B.S.); (A.C.); (R.S.); (E.P.); (F.F.); (V.S.); (G.C.)
| | - Maria Rosaria Ambrosio
- URT “Genomic of Diabetes”, Institute for Experimental Endocrinology and Oncology “G. Salvatore”, National Research Council (IEOS-CNR), Via Pansini 5, 80131 Naples, Italy; (M.R.A.); (P.F.)
| | - Elisa Magli
- Dipartimento di Sanità Pubblica, Università di Napoli Federico II, Via Pansini, 5, 80131, Naples, Italy;
| | - Giovanni Maneli
- Department of Translational Medicine, University of Naples “Federico II”, Via Pansini 5, 80131 Naples, Italy;
| | - Beatrice Severino
- Dipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano, 49, 80131 Naples, Italy; (G.A.); (B.S.); (A.C.); (R.S.); (E.P.); (F.F.); (V.S.); (G.C.)
| | - Angela Corvino
- Dipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano, 49, 80131 Naples, Italy; (G.A.); (B.S.); (A.C.); (R.S.); (E.P.); (F.F.); (V.S.); (G.C.)
| | - Rosa Sparaco
- Dipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano, 49, 80131 Naples, Italy; (G.A.); (B.S.); (A.C.); (R.S.); (E.P.); (F.F.); (V.S.); (G.C.)
| | - Elisa Perissutti
- Dipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano, 49, 80131 Naples, Italy; (G.A.); (B.S.); (A.C.); (R.S.); (E.P.); (F.F.); (V.S.); (G.C.)
| | - Francesco Frecentese
- Dipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano, 49, 80131 Naples, Italy; (G.A.); (B.S.); (A.C.); (R.S.); (E.P.); (F.F.); (V.S.); (G.C.)
| | - Vincenzo Santagada
- Dipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano, 49, 80131 Naples, Italy; (G.A.); (B.S.); (A.C.); (R.S.); (E.P.); (F.F.); (V.S.); (G.C.)
| | - Anna Leśniak
- Department of Pharmacotherapy and Pharmaceutical Care, Centre for Preclinical Research and Technology, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland; (A.L.); (M.B.-Z.)
| | - Magdalena Bujalska-Zadrożny
- Department of Pharmacotherapy and Pharmaceutical Care, Centre for Preclinical Research and Technology, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland; (A.L.); (M.B.-Z.)
| | - Giuseppe Caliendo
- Dipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano, 49, 80131 Naples, Italy; (G.A.); (B.S.); (A.C.); (R.S.); (E.P.); (F.F.); (V.S.); (G.C.)
| | - Pietro Formisano
- URT “Genomic of Diabetes”, Institute for Experimental Endocrinology and Oncology “G. Salvatore”, National Research Council (IEOS-CNR), Via Pansini 5, 80131 Naples, Italy; (M.R.A.); (P.F.)
- Department of Translational Medicine, University of Naples “Federico II”, Via Pansini 5, 80131 Naples, Italy;
| | - Ferdinando Fiorino
- Dipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano, 49, 80131 Naples, Italy; (G.A.); (B.S.); (A.C.); (R.S.); (E.P.); (F.F.); (V.S.); (G.C.)
| |
Collapse
|
5
|
Goel KK, Thapliyal S, Kharb R, Joshi G, Negi A, Kumar B. Imidazoles as Serotonin Receptor Modulators for Treatment of Depression: Structural Insights and Structure-Activity Relationship Studies. Pharmaceutics 2023; 15:2208. [PMID: 37765177 PMCID: PMC10535231 DOI: 10.3390/pharmaceutics15092208] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 08/13/2023] [Accepted: 08/19/2023] [Indexed: 09/29/2023] Open
Abstract
Serotoninergic signaling is identified as a crucial player in psychiatric disorders (notably depression), presenting it as a significant therapeutic target for treating such conditions. Inhibitors of serotoninergic signaling (especially selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI)) are prominently selected as first-line therapy for the treatment of depression, which benefits via increasing low serotonin levels and norepinephrine by blocking serotonin/norepinephrine reuptake and thereby increasing activity. While developing newer heterocyclic scaffolds to target/modulate the serotonergic systems, imidazole-bearing pharmacophores have emerged. The imidazole-derived pharmacophore already demonstrated unique structural characteristics and an electron-rich environment, ultimately resulting in a diverse range of bioactivities. Therefore, the current manuscript discloses such a specific modification and structural activity relationship (SAR) of attempted derivatization in terms of the serotonergic efficacy of the resultant inhibitor. We also featured a landscape of imidazole-based development, focusing on SAR studies against the serotoninergic system to target depression. This study covers the recent advancements in synthetic methodologies for imidazole derivatives and the development of new molecules having antidepressant activity via modulating serotonergic systems, along with their SAR studies. The focus of the study is to provide structural insights into imidazole-based derivatives as serotonergic system modulators for the treatment of depression.
Collapse
Affiliation(s)
- Kapil Kumar Goel
- Department of Pharmaceutical Sciences, Gurukul Kangri (Deemed to Be University), Haridwar 249404, Uttarakhand, India
| | - Somesh Thapliyal
- Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Srinagar Garhwal 246174, Uttarakhand, India (G.J.)
| | - Rajeev Kharb
- Amity Institute of Pharmacy, Amity University, Noida 201313, Uttar Pradesh, India
| | - Gaurav Joshi
- Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Srinagar Garhwal 246174, Uttarakhand, India (G.J.)
| | - Arvind Negi
- Department of Bioproduct and Biosystems, Aalto University, 02150 Espoo, Finland
| | - Bhupinder Kumar
- Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Srinagar Garhwal 246174, Uttarakhand, India (G.J.)
- Department of Chemistry, Graphic Era (Deemed to Be University), Dehradun 248002, Uttarakhand, India
| |
Collapse
|
6
|
Sahu B, Bhatia R, Kaur D, Choudhary D, Rawat R, Sharma S, Kumar B. Design, synthesis and biological evaluation of oxadiazole clubbed piperazine derivatives as potential antidepressant agents. Bioorg Chem 2023; 136:106544. [PMID: 37116324 DOI: 10.1016/j.bioorg.2023.106544] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Revised: 04/11/2023] [Accepted: 04/12/2023] [Indexed: 04/30/2023]
Abstract
Piperazine derivatives have been of great interest to medicinal chemists in the development of antidepressant drugs due to their distinct molecular and structural features along with their pharmacological profile. In this study, we have designed and synthesized a series of 10 compounds of piperazine clubbed oxadiazole derivatives (5a-j) and screened for their MAO inhibitory activity. Compound 5f and 5 g were found to be the most potent MAO-A inhibitors of the series with IC50 values of 0.96 ± 0.04 µM µM and 0.81 ± 0.03 µM, respectively with a selectivity index of 18-folds and 9-folds over MAO-B isoform. The compounds were found to be reversible inhibitors of MAO-A with no cytotoxicity against SH-SY5Y neuronal cells. The compounds also displayed good antioxidant activity. Further, in vivo TST studies revealed that both the compounds 5f and 5 g possessed good anti-depressant-like activity and reduced the immobility time significantly although were found inactive in FST studies. The molecular docking studies revealed that both compounds fit well at the active site of MAO-A enzyme as similar to clorgyline and form a stable complex. The results were confirmed via molecular dynamic studies which demonstrate the stable complex formation between MAO-A and 5f & 5 g. The appropriate drug-like characteristics with favourable ADMET profile, these molecules presented this piperazine clubbed oxadiazole structural framework as a key pharmacophore for the development of new antidepressant molecules along with strong candidature for further clinical investigations.
Collapse
Affiliation(s)
- Bhaskar Sahu
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, G.T Road, Moga, Punjab 142001, India
| | - Rohit Bhatia
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, G.T Road, Moga, Punjab 142001, India
| | - Dilpreet Kaur
- Department of Pharmacology, ISF College of Pharmacy, Ghal Kalan, G.T Road, Moga, Punjab 142001, India
| | - Diksha Choudhary
- Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401 Punjab, India
| | - Ravi Rawat
- School of Health Sciences & Technology, UPES University, Dehradun 248007, India
| | - Shilpa Sharma
- Department of Biotechnology, Bennett University, Greater Noida 201310, India
| | - Bhupinder Kumar
- Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Srinagar, Garhwal, Uttarakhand 246174, India; Department of Chemistry, Graphic Era (Deemed to be University), Dehradun, Uttarakhand 248002, India.
| |
Collapse
|
7
|
An insight on medicinal attributes of pyrimidine scaffold: An updated review. J Heterocycl Chem 2022. [DOI: 10.1002/jhet.4593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|